Express Scripts has determined that it will list INPEFA as a preferred product on Medicare national formularies on November 1, 2023 THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon ...
Express Scripts will include Cyltezo and both Sandoz products (Hyrimoz and unbranded adalimumab-adaz) – inflammatory disease biosimilars with competitive net costs – as preferred products on the ...
Express Scripts, the pharmacy benefits management business of the Cigna Group's Evernorth, will add three additional biosimilars to its National Preferred Formulary that it said will compete with ...
The FINANCIAL — Amgen on October 6 announced that Express Scripts will provide access to Repatha (evolocumab) through its national formulary. “Ensuring access to Repatha for appropriate patients is ...
On the heels of a similar announcement from Optum Rx, pharmacy benefit management giant Express Scripts said Monday that it will add three biosimilars to its formulary to compete with Humira. The PBM ...
The MarketWatch News Department was not involved in the creation of this content. HERCESSI(TM) becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to ...
Top of the morning to you, and a fine one it is. Birds are chirping and cool breezes are wafting by the Pharmalot campus, where the official mascots are racing about the grounds. As for us, we are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results